Circulating tumor DNA: New horizons for improving cancer treatment

Future Oncology

Volumn 11, Issue 4, 2015, Pages 545-548

  Lianos, Georgios D ^a,b   Mangano, Alberto ^c   Cho, William C ^d   Dionigi, Gianlorenzo ^c   Roukos, Dimitrios H ^a,b,e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^e Academy of Athens Biomedical Research Foundation   (Greece)

Author keywords

cancer; circulating tumor DNA; clonal evolution; genetic variation; next generation sequencing analyses; personalized medicine; recurrence; regulatory networks; tumor heterogeneity

Indexed keywords

DNA;

CANCER RECURRENCE; CANCER THERAPY; CLONAL EVOLUTION; GENETIC VARIABILITY; HUMAN; MEDICAL DECISION MAKING; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; BLOOD; HIGH THROUGHPUT SEQUENCING; NEOPLASMS;

DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS;

EID: 84923081743     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.250     Document Type: Review

References (21)

1. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 339(6127), 1546-1558 (2013).
2. Klein CA. Selection and adaptation during metastatic cancer progression. Nature 501(7467), 365-372 (2013).
3. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 501(7467), 355-364 (2013).
4. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447), 108-112 (2013).
5. Jurgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin. Cancer Res. 20(17), 4425-4435 (2014).
6. Gerlinger M, Rowan NJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
7. Pantel K, Diaz LA Jr, Polyak K. Tracking tumor resistance using 'liquid biopsies'. Nat. Med. 19(6), 676-677 (2013).
8. Chan KC, Jiang P, Zheng YW et al. Cancer genome scanning in plasma: detection of tumorassociated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211-224 (2013).
9. Leary RJ, Sausen M, Kinde I et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162 (2012).
10. Leary RJ, Sausen M, Diaz LA Jr, Velculescu VE. Cancer detection using whole-genome sequencing of cell free DNA. Oncotarget 4(8), 1119-1120 (2013).
11. Neph S, Stergachis AB, Reynolds A, Sandstrom R, Borenstein E, Stamatoyannopoulos JA. Circuitry and dynamics of human transcription factor regulatory networks. Cell 150(6), 1274-1286 (2012).
12. Tran B, Dancey JE, Kamel-Reid S et al. Cancer genomics: technology, discovery, and translation. J. Clin. Oncol. 30, 647-660 (2012).
13. Greaves M, Maley CC. Clonal evolution in cancer. Nature 481, 306-313 (2012).
14. Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat. Med. 19, 274-275 (2013).
15. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72(19), 4875-4882 (2012).
16. Bettegowda C, Sausen M, Leary R et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
17. Lawrence MS, Stojanov P, Mermel CH et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
18. Lappalainen T, Sammeth M, Friedländer MR et al. Trascriptome and genome sequencing uncovers functional variation in humans. Nature 501(7468), 506-511 (2013).
19. Hanahan, D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144 (5), 646-674 (2011).
20. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842-851 (2013).
21. Rask-Andersen M, Almén MS, Schiöth HB. Trends in the exploitation of novel drug targets. Nat. Rev. Drug. Discov. 10 (8), 579-590 (2011).